Brief: Revive Therapeutics Receives FDA Orphan Drug Designation For Liver Medication
15/02/2022 22:34
Feb 15 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION
FOR
BUCILLAMINE IN THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
DURING LIVER TRANSPLANTATION
Source text for Eikon: ID:nGNX6DK5xP
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure